UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
(Exact name of Registrant as specified in its charter) |
|
| |||
(State or other jurisdiction of incorporation) |
| (Commission File No.) |
| (IRS Employer Identification No.) |
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (
N/A
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
| Trading Symbol(s) |
| Name of Each Exchange on Which Registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§203.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§204.12b-2 of this chapter.
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On July 20, 2023, CEL-SCI Corporation (the “Company”) closed on an underwritten public offering (“Offering”) and issued 2,500,000 shares of common stock at a public offering price of $2.00 per share pursuant to the terms of an Underwriting Agreement with ThinkEquity, LLC as Representative of the several underwriters. The closing of the Offering took place on July 20, 2023. The Company received approximately $4,500,000 in net proceeds from the Offering, after deducting underwriting discounts and commissions and estimated offering expenses. The shares were sold pursuant to the Company’s effective registration statement on Form S-3 (Registration No. 333-265995) which was declared effective by the Securities Exchange Commission (the “SEC”) on July 15, 2022, and the base prospectus included therein, as amended and supplemented by the prospectus supplement dated July 17, 2023.
On July 20, 2023, the Company issued a press release announcing the closing of the offering. A copy of this press release is attached as Exhibit 99.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements related to the anticipated closing of the Offering and the amount of net proceeds expected from the Offering. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties, many of which are beyond our control, which may cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond the Company’s control, include the Company’s ability to satisfy certain conditions to closing on a timely basis or at all, as well as other risks described in the section entitled “Risk Factors” and elsewhere in the Company’s Annual Report on Form 10-K filed with the SEC on December 27, 2022 and in the Company’s other filings with the SEC, including, without limitation, its reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. |
| Description |
|
|
|
|
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 20, 2023
| CEL-SCI CORPORATION | ||
|
|
|
|
By: | /s/ Geert Kersten | ||
|
| Geert Kersten |
|
|
| Chief Executive Officer |
|
3 |
EXHIBIT 99
|
| |
|
|
|
8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com |
| COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 |
CEL-SCI ANNOUNCES CLOSING OF PUBLIC OFFERING
Vienna, VA, July 20, 2023 – CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the closing of its previously announced public offering of 2,500,000 shares of its common stock at a public offering price of $2.00 per share, for gross proceeds of $5,000,000, before deducting underwriting discounts and offering expenses.
The Company intends to use the proceeds from the offering to fund the continued development of Multikine* and for general corporate purposes.
ThinkEquity acted as sole book-running manager for the offering.
The offering is being made pursuant to an effective shelf registration statement that has been filed with the U.S. Securities and Exchange Commission (the “SEC”). The final prospectus supplement relating to the offering was filed with the SEC and is available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004, Attention: Prospectus Department.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About CEL-SCI Corporation
CEL-SCI is a clinical-stage biotechnology company focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company’s lead investigational therapy Multikine completed a pivotal Phase 3 clinical trial involving head and neck cancer, for which the Company has received Orphan Drug Status from the FDA. The Company has operations in Vienna, Virginia, and near Baltimore, Maryland.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such statements include, but are not limited to, statements about the offering. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2022. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.
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end
Cover |
Jul. 20, 2023 |
---|---|
Cover [Abstract] | |
Entity Registrant Name | CEL-SCI CORPORATION |
Entity Central Index Key | 0000725363 |
Document Type | 8-K |
Amendment Flag | false |
Entity Emerging Growth Company | false |
Document Period End Date | Jul. 20, 2023 |
Entity Incorporation State Country Code | CO |
Entity Tax Identification Number | 84-0916344 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Entity File Number | 001-11889 |
Entity Address Address Line 1 | 8229 Boone Blvd. #802 |
Entity Address City Or Town | Vienna |
Entity Address State Or Province | VA |
Entity Address Postal Zip Code | 22182 |
City Area Code | 703 |
Local Phone Number | 506-9460 |
Security 12b Title | Common Stock |
Trading Symbol | CVM |
Security Exchange Name | NYSEAMER |
-8?20$3;8T.P6BP^0"X99K>]9!:G
M
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end